SCHEMBL245261

SCHEMBL245261

CC(C)CC(NC(=O)OC(C)(C)C)C(=O)NO

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.68
CTSS P25774 3/20 0.68
CTSL P07711 2/20 0.68
CTSB P07858 1/20 0.68
CAPN1 P07384 1/20 0.59
AAK1 Q2M2I8 1/20 0.56
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MAP1LC3B Q9GZQ8 1/20 0.47
MAP1LC3A Q9H492 1/20 0.47
REN P00797 1/20 0.47
MMP13 P45452 3/20 0.47
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP8 P22894 2/20 0.47
MMP1 P03956 1/20 0.47
MMP3 P08254 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19061547 0.88 CTSK (0.67) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL4225806 0.88 CTSK (0.67) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL25293909 0.87 CTSK (0.65) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL7159331 0.87 CTSK (0.65) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL5557615 0.87 CTSK (0.65) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL7420919 0.87 CTSK (0.54) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL4576781 0.85 CTSL (0.68) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL7392267 0.85 CTSL (0.68) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL18414075 0.85 CTSS (0.72) CTSKCTSSCTSLCTSBCAPN1
SCHEMBL24741085 0.85 CAPN1 (0.74) CTSKCTSSCTSLCTSBCAPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof NAUREX, INC. (US) 2014-02-13 US disclosed
US-20120004309-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof KHAN AMIN (US) 2012-01-05 US disclosed
WO-2010065709-A2 HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF KHAN AMIN (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004309-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof GLS, HGFAC, AADAC CTSK 251/4885CTSS 416/4885CTSL 426/4885
US-20140045943-A1 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof GLS, HGFAC, AADAC CTSK 251/4885CTSS 416/4885CTSL 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.